Patents Assigned to Innovative Cellular Therapeutics CO., LTD.
-
Publication number: 20220265708Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell.Type: ApplicationFiled: January 10, 2019Publication date: August 25, 2022Applicants: Innovative Cellular Therapeutics, Inc., Innovative Cellular Therapeutics Co., Ltd.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Zhao Wu, Li Mao, Mao Bi
-
Publication number: 20210077532Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, a method of enhancing T cell-based therapy comprises administering genetically modified T cells comprising a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.Type: ApplicationFiled: December 1, 2020Publication date: March 18, 2021Applicant: Innovative Cellular Therapeutics Co., Ltd.Inventors: Lei Xiao, Zhiyuan Cao, Chengfei Pu, He Sun
-
Publication number: 20210079349Abstract: The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).Type: ApplicationFiled: November 23, 2020Publication date: March 18, 2021Applicant: Innovative Cellular Therapeutics Co., Ltd.Inventor: Zhao Wu
-
Patent number: 10918667Abstract: Compositions and methods for enhancing T cell response which increases the efficacy of CAR T cell therapy for treating cancer are described. Embodiments include a modified cell comprising an isolated nucleic acid comprising a first nucleic acid and a second nucleic acid, the first nucleic acid encoding a chimeric antigen receptor (CAR), the second nucleic acid encoding a therapeutic agent comprising at least one of IFN-?, IL-2, IL-6, IL-7, IL-15, IL-17, and IL-23. The modified cell expresses and secretes the therapeutic agent.Type: GrantFiled: June 19, 2019Date of Patent: February 16, 2021Assignee: Innovative Cellular Therapeutics Co., Ltd.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao
-
Patent number: 10869888Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, a method of enhancing T cell-based therapy comprises administering genetically modified T cells comprising a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.Type: GrantFiled: April 17, 2019Date of Patent: December 22, 2020Assignee: Innovative Cellular Therapeutics Co., Ltd.Inventors: Lei Xiao, Zhiyuan Cao, Chengfei Pu
-
Patent number: 10865382Abstract: The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).Type: GrantFiled: May 6, 2019Date of Patent: December 15, 2020Assignee: Innovative Cellular Therapeutics Co., Ltd.Inventor: Zhao Wu
-
Publication number: 20200385484Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.Type: ApplicationFiled: August 19, 2020Publication date: December 10, 2020Applicant: Innovative Cellular Therapeutics Co., Ltd.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi, Zhao Wu
-
Patent number: 10793638Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.Type: GrantFiled: March 30, 2018Date of Patent: October 6, 2020Assignee: Innovative Cellular Therapeutics Co., Ltd.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi, Zhao Wu
-
Publication number: 20200172865Abstract: Embodiments relate to a modified T cell comprising an antigen binding molecule, wherein expression and/or function of CDC42 in the modified cell has been enhanced. In embodiments, the modified cell has an increased level of cytokine release in response to an antigen that the antigen binding molecule binds as compared to a corresponding T cell that does not overexpress CDC42. In embodiments, the cytokine release comprises a cytokine release of IFN?. In embodiments, the modified cell has an enhanced migration capability in response to a chemokine as compared to a corresponding T cell that does not overexpress CDC42.Type: ApplicationFiled: December 3, 2019Publication date: June 4, 2020Applicant: Innovative Cellular Therapeutics Co., Ltd.Inventors: Chengfei Pu, Zhiyuan Cao, Lei Xiao, He Sun
-
Publication number: 20200155598Abstract: Compositions and methods for enhancing T cell response which increases the efficacy of CAR T cell therapy for treating cancer are described. Embodiments include a modified cell comprising an isolated nucleic acid comprising a first nucleic acid and a second nucleic acid, the first nucleic acid encoding a chimeric antigen receptor (CAR), the second nucleic acid encoding a therapeutic agent comprising at least one of IFN-?, IL-2, IL-6, IL-7, IL-15, IL-17, and IL-23. The modified cell expresses and secretes the therapeutic agent.Type: ApplicationFiled: June 19, 2019Publication date: May 21, 2020Applicant: Innovative Cellular Therapeutics Co., LtdInventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, He Sun
-
Patent number: 10654934Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.Type: GrantFiled: February 15, 2018Date of Patent: May 19, 2020Assignee: Innovative Cellular Therapeutics Co., Ltd.Inventors: Lei Xiao, Zhao Wu, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi
-
Patent number: 10619136Abstract: The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).Type: GrantFiled: December 8, 2016Date of Patent: April 14, 2020Assignee: Innovative Cellular Therapeutics Co., Ltd.Inventor: Zhao Wu
-
Publication number: 20200078403Abstract: Embodiments of the present disclosure include a method for treating Systemic Lupus Erythematosus (SLE) using CD19 CAR T cells. The method includes administering to the human patient a pharmaceutically effective amount of a population of T cells of the human patient that express a chimeric antigen receptor (CAR) that comprises the amino acid sequence of, e.g., SEQ ID NO: 23.Type: ApplicationFiled: September 12, 2019Publication date: March 12, 2020Applicants: INNOVATIVE CELLULAR THERAPEUTICS CO., LTD., ZHEJIANG UNIVERSITYInventors: LEI XIAO, CHENGFEI PU, ZHAO WU, LINRONG LU
-
Publication number: 20200071400Abstract: The present disclosure relates to compositions and methods for enhancing CAR T therapy through uses of co-stimulation. Some embodiments relate to an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR) and an agent associated with a co-stimulatory molecule, the CAR comprising an intracellular domain of a costimulatory molecule.Type: ApplicationFiled: August 27, 2019Publication date: March 5, 2020Applicant: INNOVATIVE CELLULAR THERAPEUTICS CO., LTD.Inventors: ZHIYUAN CAO, CHENGFEI PU, LEI XIAO, ZHAO WU
-
Publication number: 20200069732Abstract: Embodiments relate to a modified cell comprising an antigen binding molecule, and the expression and/or function of one or more genes in the modified cell has been enhanced or reduced or eliminated. The one or more genes include CXCR3, SLC1A3, YAP, TIGIT, S1P1, and IL-35. In embodiments, the cell is a T cell, a dendritic cell, a NK cell, or a macrophage cell. In embodiments, the antigen binding molecule comprises a chimeric antigen receptor (CAR) and/or the second antigen binding molecule is a T Cell Receptor (TCR).Type: ApplicationFiled: August 29, 2019Publication date: March 5, 2020Applicant: Innovative Cellular Therapeutics Co., Ltd.Inventors: Zhiyuan Cao, Chengfei Pu, Lei Xiao, Zhao Wu
-
Patent number: 10561686Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion in vivo and/or in vitro. For example, a cell may comprise a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR may recognize a surface molecule of a blood cell.Type: GrantFiled: September 28, 2018Date of Patent: February 18, 2020Assignee: Innovative Cellular Therapeutics Co., Ltd.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Zhao Wu
-
Publication number: 20200030424Abstract: Embodiments herein relate to humanized CD19 antibodies and disease treatment using the antibodies. For example, a subject having a CD19 positive tumor may be administered a therapeutically effective amount of the humanized antibody.Type: ApplicationFiled: October 11, 2019Publication date: January 30, 2020Applicant: Innovative Cellular Therapeutics Co., Ltd.Inventors: Zhao Wu, Zhigang Liu, Lei Xiao, Chengfei Pu, Zhiyuan Cao
-
Patent number: 10493139Abstract: Embodiments herein relate to humanized CD19 antibodies and disease treatment using the antibodies. For example, a subject having a CD19 positive tumor may be administered a therapeutically effective amount of the humanized antibody.Type: GrantFiled: January 22, 2018Date of Patent: December 3, 2019Assignee: Innovative Cellular Therapeutics Co., Ltd.Inventors: Zhao Wu, Zhigang Liu, Lei Xiao, Chengfei Pu, Zhiyuan Cao
-
Publication number: 20190316086Abstract: The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).Type: ApplicationFiled: May 6, 2019Publication date: October 17, 2019Applicant: Innovative Cellular Therapeutics Co., Ltd.Inventor: Zhao Wu
-
Publication number: 20190314411Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, a method of enhancing T cell-based therapy comprises administering genetically modified T cells comprising a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.Type: ApplicationFiled: April 17, 2019Publication date: October 17, 2019Applicant: Innovative Cellular Therapeutics Co., Ltd.Inventors: Lei Xiao, Zhiyuan Cao, Chengfei Pu, He Sun